Roger Montgomery on Sirtex, page-94

First-half revenues for SRX in fiscal 2015 jumped 37% to AUS$81m on rising demand for SIR-Speres, the company's only marketed product. Profit was up 58% year-on-year, at AUS$18m. The company was planning to spend AUS$8m or so on marketing in the second half of financial 2015 in anticipation of approval and launch of a first-line therapy. At least it can put this cash back in its wallet.
The company may now turn to its trials in other cancers; Sirtex is testing SIR-Spheres in hepatocellular carcinoma and renal cell carcinoma, and academic researchers are trying the technology in breast cancer and melanoma.
The failing over-emo gothic-styled market that is the ASX has overreacted, attached as it is to the world's worst performing economy, even Treasury Secretary Hockey is talking the Australian economy into an apocalypse, while southern European economies r on the mend. The ASX overrreacts to anything negative. My bet is that SRX will recover based on liver cancer sales alone and a few other things no longer priced into the stock, will come back in. If SRX was listed on NASDAQ, the SRX SP might have fallen to $30 perhaps but SRX investors would still be positive in outlook. Nothing but pessimism remains in Australia these days. When the lights go out, only complacency will be left in the world's resource-rich but most downramped economy. Even the Treasury Secretary Hockey downramps Australia's economy. What hope is there?